Fingolimod in Endovascular Treatment of Ischemic Stroke

Summary

Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with acute ischemic stroke as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. This study aim to determine whether fingolimod enhance the action of endovascular treatment for acute ischemic stroke

Timeline

Start

2020-11-12

Primary completion

2022-12-30

Completion

2023-12-30

Drugs

Indications